Management of Treatment-Experienced HIV-Infected Patients
Summary
- Persistently detectable virus at insufficient levels for resistance testing (HIV-1 RNA 200-1000 copies/mL) is distinct from clinically irrelevant “blips”
- Initial focus should be to assess adherence and potential for drug–drug or drug–food interactions
- Considerable data support modifying the regimen of treatment–experienced patients to include 3 fully active agents or a fully active ritonavir-boosted PI with other fully or partially active drugs or dolutegravir in INSTI-naive patients plus 2 NRTIs where at least 1 is fully active[Aboud 2019]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content